HomeIPSEY • OTCMKTS
Ipsen ADR Rep 1/4 Ord Shs
$29.88
Mar 28, 8:10:00 PM GMT-4 · USD · OTCMKTS · Disclaimer
US listed security
Previous close
$29.41
Day range
$29.80 - $29.95
Year range
$26.97 - $34.34
Market cap
9.18B EUR
Avg Volume
1.16K
CDP Climate Change Score
B
Financials
Income Statement
Revenue
Net income
(EUR)Dec 2023Y/Y change
Revenue
Operating expense
Net income
Net profit margin
Earnings per share
EBITDA
Effective tax rate
Total assets
Total liabilities
(EUR)Dec 2023Y/Y change
Cash and short-term investments
528.40M-54.81%
Total assets
6.32B12.62%
Total liabilities
2.50B10.03%
Total equity
3.82B
Shares outstanding
82.72M
Price to book
0.64
Return on assets
Return on capital
Net change in cash
(EUR)Dec 2023Y/Y change
Net income
Cash from operations
Cash from investing
Cash from financing
Net change in cash
Free cash flow
About
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on transformative medicines in three therapeutic areas: oncology, rare disease and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales. Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index. The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. Wikipedia
Founded
1929
Website
Employees
5,325
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
Search
Clear search
Close search
Google apps
Main menu